Published in Aliment Pharmacol Ther on July 01, 1998
Proton pump inhibitors and gastric neoplasia. Gut (2006) 1.90
Safety of the long-term use of proton pump inhibitors. World J Gastroenterol (2010) 1.55
Effects of proton pump inhibitors on gastric emptying: a systematic review. Dig Dis Sci (2009) 1.15
Antiulcer drugs and gastric cancer. Dig Dis Sci (2005) 1.01
The stomach in health and disease. Gut (2015) 0.95
Delivery of radiofrequency energy to the gastroesophageal junction (Stretta procedure) for the treatment of gastroesophageal reflux disease. Surg Endosc (2005) 0.95
Helicobacter pylori infection and gastrointestinal hormones:a review. World J Gastroenterol (2000) 0.90
Brain-gut axis in the pathogenesis of Helicobacter pylori infection. World J Gastroenterol (2014) 0.90
Gastric carcinoid tumors without autoimmune gastritis in Japan: a relationship with Helicobacter pylori infection. Dig Dis Sci (2002) 0.88
Long-term proton pump inhibitor use and gastrointestinal cancer. Curr Gastroenterol Rep (2008) 0.88
Are proton pump inhibitors a double-edged sword in the treatment of Helicobacter pylori infection? Ann Gastroenterol (2012) 0.75
Hypergastrinaemia in patients infected with Helicobacter pylori treated with proton pump inhibitors. Gut (2005) 0.75
Hypergastrinaemia with long-term omeprazole treatment. Aliment Pharmacol Ther (1999) 0.75
Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut (2006) 9.03
Helicobacter pylori and atrophic gastritis: importance of the cagA status. J Natl Cancer Inst (1995) 6.07
Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol (1998) 5.77
Laparoscopic or conventional Nissen fundoplication for gastro-oesophageal reflux disease: randomised clinical trial. The Netherlands Antireflux Surgery Study Group. Lancet (2000) 5.31
Long-term sequelae of Helicobacter pylori gastritis. Lancet (1995) 4.26
Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med (1996) 4.11
Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med (1994) 4.00
[Occult blood studies of the feces obsolete]. Ned Tijdschr Geneeskd (1996) 3.29
Nurse endoscopists perform colonoscopies according to the international standard and with high patient satisfaction. Endoscopy (2012) 3.27
Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet (1999) 3.25
Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med (1989) 3.03
Helicobacter pylori eradication and gastric cancer: when is the horse out of the barn? Am J Gastroenterol (2009) 2.89
Randomised trial of glutamine-enriched enteral nutrition on infectious morbidity in patients with multiple trauma. Lancet (1998) 2.84
Potential role of molecular mimicry between Helicobacter pylori lipopolysaccharide and host Lewis blood group antigens in autoimmunity. Infect Immun (1996) 2.75
The prevalence of Helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther (1995) 2.74
Colonoscopy perforation rate, mechanisms and outcome: from diagnostic to therapeutic colonoscopy. Endoscopy (2009) 2.70
Complications of single-balloon enteroscopy: a prospective evaluation of 166 procedures. Endoscopy (2010) 2.62
Clostridial toxin in faeces of healthy infants. Lancet (1978) 2.58
Short-term esophageal stenting in the management of benign perforations. Am J Gastroenterol (2010) 2.55
Double-balloon enteroscopy: indications, diagnostic yield, and complications in a series of 275 patients with suspected small-bowel disease. Endoscopy (2006) 2.43
Increasing incidence of Barrett's oesophagus in the general population. Gut (2005) 2.34
Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease. Am J Gastroenterol (1999) 2.33
High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol (2010) 2.32
Role of cobalamin intake and atrophic gastritis in mild cobalamin deficiency in older Dutch subjects. Am J Clin Nutr (1998) 2.26
Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis. Gastroenterology (1994) 2.22
Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol (1997) 2.17
Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am J Gastroenterol (1995) 2.12
The incidence of Barrett's oesophagus and oesophageal adenocarcinoma in the United Kingdom and The Netherlands is levelling off. Aliment Pharmacol Ther (2014) 2.07
The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol (2009) 2.04
[Acute dysphasia: often there is a readily treatable cause]. Ned Tijdschr Geneeskd (2003) 2.03
A comparison of 3 types of covered metal stents for the palliation of patients with dysphagia caused by esophagogastric carcinoma: a prospective, randomized study. Gastrointest Endosc (2001) 2.03
Differential features of gastric cancer patients, either Helicobacter pylori positive or Helicobacter pylori negative. Ital J Gastroenterol Hepatol (1999) 2.02
Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia. Am J Gastroenterol (2012) 1.98
Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta (2002) 1.98
Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses. J Virol (2001) 1.95
Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br J Cancer (2009) 1.93
Long term serological surveillance after treatment of Helicobacter pylori infection. Gut (1991) 1.90
Seroconversion for Helicobacter pylori. Lancet (1993) 1.88
Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. Scand J Immunol (1996) 1.86
Long-term esophageal cancer risk in patients with primary achalasia: a prospective study. Am J Gastroenterol (2010) 1.85
Systematic review: the global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther (2009) 1.83
Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis. Lancet (1987) 1.83
Analysis of the lympho-plasmacytic infiltrate in Crohn's disease with special reference to identification of lymphocyte-subpopulations. Gut (1976) 1.83
Optimal resource allocation in colonoscopy: timing of follow-up colonoscopies in relation to adenoma detection rates. Endoscopy (2013) 1.82
Human papillomavirus detection and comorbidity: critical issues in selection of patients with oropharyngeal cancer for treatment De-escalation trials. Ann Oncol (2013) 1.77
The detection, surveillance and treatment of premalignant gastric lesions related to Helicobacter pylori infection. Helicobacter (2007) 1.77
Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group. Eur J Gastroenterol Hepatol (1995) 1.74
Cholesterol crystal embolization in the Netherlands. Arch Intern Med (1996) 1.74
Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline and trovafloxacin in The Netherlands. J Antimicrob Chemother (1999) 1.73
Helicobacter pylori: a true carcinogen? Eur J Gastroenterol Hepatol (1998) 1.72
Treatment of the dumping syndrome with the somatostatin analogue SMS 201-995. Ann Surg (1988) 1.72
Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer (1996) 1.71
Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer (2008) 1.69
Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy. Eur J Clin Invest (2001) 1.69
Time-trends in gastroprotection with nonsteroidal anti-inflammatory drugs (NSAIDs). Aliment Pharmacol Ther (2010) 1.68
Effect of transport medium and transportation time on culture of Helicobacter pylori from gastric biopsy specimens. J Clin Pathol (1993) 1.66
HLA-DR phenotypes in Spanish coeliac children: their contribution to the understanding of the genetics of the disease. Gut (1983) 1.65
Impaired anamnestic cellular immune response in patients with Crohn's disease. Gut (1975) 1.65
Parietal cell protrusions and fundic gland cysts during omeprazole maintenance treatment. Hum Pathol (2000) 1.62
Helicobacter pylori and the birth cohort effect: evidence of a continuous decrease of infection rates in childhood. Am J Gastroenterol (1997) 1.62
Radioimmunoassay of cholecystokinin in human tissue and plasma. Clin Chim Acta (1983) 1.61
Clinical outcome of progressive stenting in patients with anastomotic strictures after orthotopic liver transplantation. Endoscopy (2013) 1.61
Systematic review: Rebound acid hypersecretion after therapy with proton pump inhibitors. Aliment Pharmacol Ther (2007) 1.59
Nickel-responsive induction of urease expression in Helicobacter pylori is mediated at the transcriptional level. Infect Immun (2001) 1.59
Explaining the bias in the 23S rRNA gene mutations associated with clarithromycin resistance in clinical isolates of Helicobacter pylori. Antimicrob Agents Chemother (1998) 1.56
Prevalence of autoimmune pancreatitis and other benign disorders in pancreatoduodenectomy for presumed malignancy of the pancreatic head. Dig Dis Sci (2012) 1.56
Comparative genomic hybridisation. Mol Pathol (1999) 1.56
Cholecystokinin receptors in human pancreas and gallbladder muscle: a comparative study. Gastroenterology (1996) 1.55
Satiety effects of cholecystokinin in humans. Gastroenterology (1994) 1.55
Progression from colorectal adenoma to carcinoma is associated with non-random chromosomal gains as detected by comparative genomic hybridisation. J Clin Pathol (1998) 1.54